

PlentiPlex™ MYD88


Assists diagnosis of lymphomas

PlentiPlex™ MYD88 L265P assay is intended for *in vitro* diagnosis of lymphomas and combines ease-of-use with high sensitivity. The obtained results of the PlentiPlex™ MYD88 L265P assay can be used for discrimination between patients with Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and non-Hodgkin lymphoma.

Fast and simple diagnosis of lymphomas

Results in less than three hours


Purify DNA



Run PCR



Analyse data



PlentiPlex™ MYD88 workflow. Analysis utilizing the PlentiPlex™ MYD88 technology only requires three simple steps. The entire workflow can be performed within a few hours from sample to result, with little hands-on time and no special training required.


- Reliable and simple readout
- Applicable in most standard laboratories
- No false positives
- Minimum hands-on time



PlentiPlex™ MYD88

PlentiPlex™ MYD88 utilizes PentaBase's proprietary INA® technology for sensitive detection of the L265P somatic mutation in lymphomas. The technology comprises HydrolEasy™ probes, SuPrimers™ and BaseBlockers™ to improve signal-to-noise ratio, specificity and sensitivity and to suppress wildtype amplification, respectively.

- High sensitivity
- Offered as pre-dispensed Ready-to-use and Dispense-ready assays
- Compatible with most types of DNA purification
- Quantitative readout



PlentiPlex™ MYD88 readout. Identification of the MYD88 L265P mutation is simple utilizing the PlentiPlex™ MYD88 method. The analysis is based on amplification curves and does not require advanced technical skills.

Sensitive MYD88 L265P detection LOD 0.25%

PentaBase

PentaBase is a knowledge-based, ISO-certified real-time PCR focused company from 2006 founded and managed by researchers in Denmark. We have local *in-house* production of custom oligonucleotides based on our own proprietary DNA chemistry, known as Intercalating Nucleic Acid (INA®). We specialize in manufacturing of real-time PCR probes for IVD companies and development of *in vitro* diagnostic assays for real-time PCR with focus on detection of somatic mutations in cancer. For more than 10 years, we have created products for researchers and medical professionals exploring new treatments and helping patients worldwide.

